Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 16/20 | 0.73 |
| ▸ | DRD2 | P14416 | 11/20 | 0.73 |
| ▸ | HTR2A | P28223 | 9/20 | 0.73 |
| ▸ | HTR2C | P28335 | 9/20 | 0.73 |
| ▸ | HTR2B | P41595 | 9/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841158 | 0.94 | SIGMAR1 (0.64) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6836332 | 0.91 | SIGMAR1 (0.71) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6836321 | 0.85 | SIGMAR1 (0.62) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6841155 | 0.84 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6840744 | 0.84 | SIGMAR1 (1.00) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6841101 | 0.80 | DRD2 (0.55) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6841463 | 0.79 | SIGMAR1 (0.60) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6843421 | 0.78 | SIGMAR1 (0.65) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6841548 | 0.78 | SIGMAR1 (0.88) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL27081326 | 0.77 | SMN1; SMN2 (0.59) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | claimed |
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | OPRM1, OPRL1, OPRD1 | SIGMAR1 11/4885DRD2 134/4885HTR2A 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.